FDA Releases Data Integrity Guidance
The agency published guidance on data integrity as it is relates to CGMP compliance.
On April 14, 2016, FDA published Data Integrity and Compliance with CGMP, which addresses the role of data integrity in CGMP for drug manufacturing, finished pharmaceuticals, and positron emission tomography drugs, as required by 21 Code of Federal Regulations (CFR) parts 210, 211, and 2012. The guidance has been issued in response to an increasing amount of data integrity violations found by the agency during CGMP inspections. According to FDA, data integrity CGMP violations have led to FDA warning letters, import alerts, and consent decrees. The new guidance answers data integrity questions in the hope of clarifying what FDA expects from manufacturers.
The guidance states that data should be reliable and accurate, and companies should implement effective strategies to manage data integrity risks. Along with clarifying the definition of data integrity terms, the guidance addresses the exclusion of CGMP data, workflow validation, data access, audits, electronic records, and personnel training. FDA also clarifies sampling and testing requirements and how to address data integrity problems.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
